There have been very few multicenter studies of the relationship between the use of antifungals and resistance to them. We investigated the antifungal susceptibility of 1,301 clinical isolates of Candida collected from nine Korean hospitals during a 3-month period in 2006 to explore the existence of this type of relationship. Antifungal usage in the preceding year, defined as the daily dose per 1,000 patient days (DDD/1,000 PD), was calculated for each hospital. Resistance to fluconazole, itraconazole, and amphotericin B was detected in 2, 9, and 0.2% of the isolates, respectively. The MIC 50 /MIC 90 values were 0.03/0.125 mg/L for voriconazole, 0.06/ 0.25 mg/l for caspofungin, and 0.03/0.125 mg/l for micafungin. The total usage of systemic antifungals varied considerably among the nine hospitals, ranging from 6.1 to 96.2 DDD/1,000 PD. No relationship was found between the use of fluconazole (MIC ]64 mg/l) or itraconazole (MIC ]1 mg/l) and resistance in the Candida species (P0.05). However, significant correlations were found between the percentage of Candida isolates that were non-susceptible to fluconazole (MIC ]16 mg/l) and fluconazole usage (r 00.733, P00.025) or total antifungal usage (r00.767, P00.016).
Introduction
The number of fungal infections caused by Candida species has increased substantially over the past two decades due to increased numbers of immunocompromised patients and patients hospitalized with serious underlying diseases [1, 2] . Candida-specific surveillance programs, which have provided valuable information regarding resistance trends and the distribution of species in various countries [3Á6] , have revealed an increase in the prevalence of fungal infections caused by non-C. albicans Candida species such as C. glabrata, C. krusei, and C. parapsilosis [3Á5] . Moreover, it appears that marked differences exist in terms of species distribution and antifungal drug susceptibility among different countries. These investigations underscore the need for continued international surveillance to monitor trends in the distribution and drug susceptibility of Candida species [7, 8] . However, few nationwide surveillance studies of Candida have been conducted in Korea [9] .
Although the relationship between antibacterial drug use and the development of resistance has been evaluated in several studies [10, 11] , few multicenter surveillance studies on the relationship between antifungal drug use and resistance have been conducted. Moreover, concern is growing about possible changes in the species distribution and azole susceptibility of Candida isolates given the increasing use of antifungal drugs [3, 12, 13] . Therefore, we investigated the in vitro antifungal susceptibility and species distribution of Candida isolates recovered from clinical specimens at nine Korean university hospitals and the antifungal usage at each of these facilities. The objectives of these studies were to assess the percentage of clinical Candida isolates that were resistance to six antifungal agents and to determine if there was a relationship between the frequency of antifungal-resistant Candida species and antifungal usage at these university hospitals.
Materials and methods

Study design
A prospective surveillance study was conducted at nine university hospitals (AÁI) located throughout Korea to assess the nationwide distribution of Candida species. Among the nine hospitals, three (A, C, and D) had more than 1,000 beds, while the other six had 500Á 1,000 beds. During a 3-month period from July to September 2006, the participating laboratories were required to collect clinical isolates that were identified as Candida species. In addition, the annual usage of systemic antifungal agents for patients admitted to each hospital between January and December 2005 was determined by calculating the number of defined daily doses per 1,000 patient days (DDD/1,000 PD), as specified by the WHO ATC/DDD system (www. whocc.no/atcddd/) and DDD measurement methodology [14, 15] .
Candida strains
Using routine culture methods, isolates were recovered from clinical specimens of patients admitted to each of the participating institutions. The processing of the samples for recovering Candida isolates was usually performed in conjunction with, and as an extension of, the procedure employed for the isolation of bacteria [16] . The isolates were cultured from blood, urine, respiratory specimens (sputum, bronchoalveolar lavage, throat swab, tracheal aspirate), abscesses/wounds, central venous catheter (CVC) tips, peritoneal or pleural fluids, or other sites (e.g., vaginal secretions, drains, other medical devices). The exact procedures used to isolate and recover the organisms varied among the hospitals. Duplicate isolates of the same Candida species from the same patient were excluded. In total, 1,301 isolates were submitted to Chonnam National University Hospital (CNUH) for identification and in vitro antifungal susceptibility testing. Upon arrival the isolates were purified by subculturing to CHROMagar Candida (BBL; Becton Dickinson, Sparks, MD, USA) and their identification was determined by colony morphology on this medium and the use of a commercial biochemical systems (API 20C; bioMérieux, Marcy L'É toile, France, or the Vitek 2 system; Vitek 2 YST, bioMérieux).
Antifungal susceptibility testing
The in vitro MICs of the isolates to amphotericin B (Sigma, St. Louis, MO, USA), voriconazole (Pfizer, Sandwich, UK), fluconazole (Pfizer), itraconazole (Janssen Pharmaceutica, Beerse, Belgium), caspofungin (Merck, Whitehouse Station, NJ, USA), and micafungin (Astellas Pharma Inc., Tokyo, Japan) were determined by the broth microdilution assay procedures of the Clinical and Laboratory Standards Institute (CLSI) [17] . The minimal inhibitory concentration (MIC) endpoints were read after 24 h of incubation in air at 358C for caspofungin and micafungin [18, 19] , and after 48 h of incubation for all other drugs [17] . The MIC of amphotericin B was defined as complete inhibition of growth, while the MICs of fluconazole, itraconazole, voriconazole, caspofungin, and micafungin were defined as the lowest concentrations that produced a prominent decrease in turbidity (approximately 50%) relative to a drug-free control [17] . Two reference strains, C. parapsilosis ATCC 22019 and C. krusei ATCC 6258, were included as quality control isolates in each test.
The interpretive susceptibility criteria used for fluconazole and itraconazole were those specified by the CLSI [17] . For fluconazole, isolates with MICs 58 mg/ ml were considered susceptible, those with MICs between 16 and 32 mg/ml were considered susceptible dose-dependent (SDD), and yeasts with MICs ]64 mg/ ml were considered resistant. Isolates of C. krusei are considered to be fluconazole-resistant, irrespective of the MIC. In the case of itraconazole, isolates with MICs 50.125 mg/ml were considered susceptible, while those with MICs between 0.25 and 0.5 mg/ml were regarded as SDD, and yeasts having MICs ]1 mg/ml were considered resistant. For voriconazole, we used the tentative interpretive breakpoints recently established for its use with Candida species (i.e., susceptible, 51 mg/ml; SDD, 2 mg/ml; and resistant, ]4 mg/ml) [20] . The percentage of antifungal-resistant isolates (% resistance) was calculated as the number of resistant isolates/number of isolates tested, while the percentage of non-susceptible isolates (% non-susceptibility) was calculated as the number of resistant or SDD isolates/ number of isolates tested.
Statistical analysis
Spearman's rank correlation coefficient (r 2 ) and its corresponding P-value were calculated from the relationships between antifungal usage and resistance at each hospital. P B0.05 was considered to be significant in both analyses.
Results
The rank order of the annual usage of systemic antifungal agents at the nine hospitals during 2005 is shown in Table 1 . The total antifungal usage among nine Korean hospitals varied considerably, ranging from 96.2 (hospital A) to 6.1 DDD/1,000 PD (Hospital I). The total usage of azole antifungals (fluconazole, itraconazole, and voriconazole) also varied, ranging from 71.4 (Hospital A) to 3.1 DDD/1,000 PD (Hospital I). The total usage of each antifungal was as follows; amphotericin B (30.7%), itraconazole (32.3%), fluconazole (30.0%), voriconazole (3.3%), lipid formulation of amphotericin B (2.5%), and caspofungin (1.2%). Azole antifungals represented 65.6% of the total antifungal employed at the nine hospitals.
In total, 1,301 Candida isolates were recovered from clinical specimens processed in the nine hospitals during a 3-month surveillance period in 2006 ( Table 2 ). The Candida species isolated from all clinical specimens included C. albicans (735, 56.5%), C. tropicalis (235, 18.1%), C. glabrata (166, 12.8%), C. parapsilosis (116, 8.9%), C. krusei (10, 0.8%), C. guilliermondii (10, 0.8%), and 29 others. In comparison, the most frequently recovered Candida species from blood samples was C. parapsilosis (37.6%), followed by C. albicans (27.1%), C. tropicalis (23.5%), and C. glabrata (7.6%).
In terms of the clinical specimens, urine was the most common source of the isolates (36.4%), followed by the respiratory tract (30.2%), blood (13.1%), and pus (6.7%). The proportion of urinary isolates of all Candida isolates varied from 22.3 to 77.7% among the samples studied at participating hospitals, but there was no relationship between antifungal use and the percentage of urinary isolates among these facilities (P 0.05).
The percentages of non-C. albicans Candida species among the isolates collected are shown in Fig. 1 , in order of antifungal usage. The stacked bars show the usage of antifungal agents, defined as DDD/1,000 PD. While C. albicans was the predominant species from all clinical specimens at all of the hospitals, ranging from 65.1 (hospital E) to 44.3% (hospital G), non-C. albicans Candida species accounted for more than half of the isolates from blood cultures, ranging from 89.5 (hospital B) to 55.6% (hospital I). No relationship was found between the percentage of non-C. albicans Candida isolates and antifungal usage.
The in vitro antifungal susceptibility of the 1,301 isolates to six antifungal agents is shown in Table 3 . The MIC 50 /MIC 90 values were 0.125/4 mg/ml for fluconazole, 0.06/1 mg/ml for itraconazole, 0.03/0.125 mg/ml for voriconazole, 0.5/0.5 mg/ml for amphotericin B, 0.06/0.25 mg/ml for caspofungin, and 0.03/0.125 mg/ml for micafungin. No significant differences in MIC 50 and MIC 90 were detected for each of the six antifungal agents between Candida isolates recovered from blood and those obtained from samples collected at other sites. Resistance to fluconazole was found in only 2% (26/1,301) of the Candida isolates, while SDD resistance was found in 3.2% of the isolates (41/1,301). Among the C. albicans, C. tropicalis, and C. parapsilosis isolates, only one C. tropicalis isolate was fluconazole-resistant while one C. albicans isolate was fluconazole-SDD. Of 166 C. glabrata isolates, 4.8% were fluconazole-resistant, while 22.3% were fluconazole-SDD. In total, 8.8 The range of amphotericin B MICs for all of the isolates was 0.125Á2.0 mg/ml. Amphotericin B MICs of 2 mg/ml were found in only 0.2% of the isolates (two C. haemulnoii isolates and one C. parapsilosis isolate). All other isolates were susceptible to amphotericin B with MICs of 1 mg/ml or less. The range of caspofungin and micafungin MICs for all of the isolates was 0.03Á2.0 mg/ ml; however, an MIC of 51.0 mg/ml was seen in most of the isolates. Higher MICs (2 mg/ml) were found on with C. parapsilosis (five strains for caspofungin and two strains for micafungin).
The relationship between antifungal usage (total or individual) and the frequency of resistance among the Candida species was assessed by Spearman correlation analysis. No statistically significant relationship was found between antifungal usage and the presence of itraconazole-resistant (MIC ]1 mg/ml) or non-susceptible (MIC ]0.25 mg/ml) Candida species (P 0.05). The percentage of Candida isolates that were resistant or non-susceptible to fluconazole at the nine hospitals is shown in Fig. 2 , in order of total antifungal usage. No correlation was found between antifungal usage and fluconazole resistance (MIC ]64 mg/ml). However, a positive correlation was found between the percentage of Candida isolates that were non-susceptible to fluconazole (MIC ]16 mg/ml) and total antifungal usage (r00.767, P 00.016). A correlation was also found between fluconazole usage and the percentage of fluconazole non-susceptible Candida isolates (r00.733, P 00.025).
Discussion
No data concerning the use of antifungal drugs in Korea has previously been reported. We identified considerable variation in total antifungal usage at nine Korean hospitals, ranging from 6.1 to 96.2 Fig. 1 Antifungal usage compared to the percentage of non-C. albicans Candida species among Candida isolates from all clinical specimens (circle and broken line) and blood (diamond and solid line) at nine Korean hospitals (AÁI). Stacked bars represent the usage of antifungal agents, defined as the daily dose /1,000 patient days (DDD/1,000 PD). DDD/1,000 PD. The total use of antifungals at each of the nine Korean hospitals was still lower than that of a tertiary-care teaching hospital in the USA ( 1,000 DDD/1,000 PD) [21] . However, most hospitals in our study showed higher total antifungal usage than that of hospitals in northern France (mean 10.57 DDD/1,000 PD) [22] . Differences in antifungal usage among Korean hospitals may be explained by variation in the incidence of severe fungal infections, culture, education, and regulations at each hospital. Higher total antifungal usage was noted in hospitals with 1,000 beds (hospitals A, C, D) than in the other six hospitals, which each had 500Á1,000 beds. The use of newer antifungals such as voriconazole and caspofungin was found in only three hospitals (A, C, D). Among the hospitals with 500Á1,000 beds, hospital B, which reported a higher frequency of severe infections due to a higher population of immunocompromised patients (mainly hematological malignancies), also had greater antifungal usage.
To determine the relationship between antifungal usage and resistance, we assessed Candida isolates from blood and other clinical sources. Although the clinical significance of isolating Candida at sites other than sterile fluids is not well defined, Candida colonization of non-sterile body sites (e.g., upper respiratory samples, urine, wound swabs) has been identified as a specific independent risk factor for Candida bloodstream infections (BSI) in critically ill patients [23, 24] . Additionally, it is possible that after exposure to antifungal agents, mucosal colonization by antifungalresistant strains may frequently precedes clinical infection. Urine (36.4%) was found to be the most common source of Candida isolates and this finding is similar to that noted in a previous report [25] . The incidence of candiduria has increased in recent years, particularly in patients admitted to intensive care units (ICUs), and specially in patients requiring prolonged urinary catheterization or receiving broad-spectrum antibiotics [26] .
C. albicans continues to play a dominant role as the cause of BSI in many hospitals [3,5Á9] . However, non-C. albicans Candida species accounted for 72.9% of all Candida blood culture isolates from the nine hospitals. Although C. albicans was the predominant species (44.3 to 65.1%) from all clinical specimens at all of the hospitals, non-C. albicans Candida species ranged from 55.6 to 89.5% of all isolates recovered in blood cultures. However, there was no relationship between the percentage of non-C. albicans Candida isolates (blood or all specimens) and antifungal usage. This suggests that the frequency of non-C. albicans Candida species recovery may be influenced not only by antifungal exposure, but also by the use of CVC, antibiotics, or other supportive care measures used at specific institutions [27, 28] .
During the 3-month study period, the Candida species that was most frequently recovered from blood samples was C. parapsilosis; in fact, it was the predominant species in five of the nine hospitals studied. Pfaller et al. [5] reported variation in the rank order and frequency of various Candida species over time and geographic area. We also found variation in the rank order of occurrence of various Candida species causing bloodstream infections over time and by hospital. The rising incidence of candidemia due to C. parapsilosis is often associated with CVC-related candidemia, which occurs in non-neutropenic patients receiving total parenteral nutrition [28, 29] . Although 37.6% of Candida isolates from blood were C. parapsilosis during the study period, C. parapsilosis was cultured from CVC tips much less commonly (20%) than were C. albicans and C. tropicalis. The reason for this remains unclear. However, a trend for a lower frequency of isolation of C. parapsilosis from CVC tips compared with that from blood cultures has been reported previously in a multicenter study in Taiwan. In this investigation, 18.1% (21/116) of the Candida isolates recovered from blood and 8.5% (4/47) from CVC tip isolates were C. parapsilosis [25] . We noted that some clinicians tended to remove CVCs and discard them without requesting tip cultures, especially in instances of C. parapsilosis fungemeia. In addition, the semiquantitative roll-plate catheter culture, which is the most frequently used method, is less sensitive in detecting fungal colonization of long-term CVC usage. This may be the result of the fact that it only detects colonization of the external surface of the catheter, rather than intraluminal area [30, 31] .
Our findings indicate that the current rate of resistance to six antifungals among the Candida species in Korea is quite low. The percentage of fluconazoleand itraconazole-resistant isolates was 2 and 9%, respectively, consistent with other reports [25, 32, 33] . In addition, based on tentative breakpoints [20] , no voriconazole resistance was identified among the 1,301 isolates, and MICs of 2.0 mg/ml (SDD) were observed in only six C. glabrata isolates. The range of caspofungin and micafungin MICs for all of the isolates was 0.03Á2.0 mg/ml, and MICs of 2 mg/ml were found in only a few C. parapsilosis isolates. The latter finding is similar to our previous report [34] and may reflect the limited use (only three of nine hospitals) of echinocandin drugs in Korean hospitals.
Since its introduction in 1990, fluconazole has been suggested to be a contributing factor in the changing epidemiology of candidal infections [35Á37] . This contribution may be manifested as acquired fluconazole resistance of C. albicans isolated from oropharyngeal candidiasis in patients with AIDS [38] or as an increased prevalence of candidemia due to C. krusei and C. glabrata, organisms that are inherently or variably resistant to fluconazole [36, 37] . Although fluconazole usage varied considerably among the nine hospitals in this study, we did not identify a significant relationship between antifungal usage and the presence of fluconazole-(MIC ]64 mg/l) resistant Candida species. The reason for this is likely due to the low percentages of C. glabrata isolates recovered from clinical specimens (8.9%). In addition, the percentages of fluconazole-resistant isolates in all nine hospitals were within a restricted low range (0Á3.3%).
We found a significant relationship between fluconazole use and fluconazole non-susceptible (MIC ]16 mg/ml) Candida isolates. This suggests that antifungal usage apparently led to an increase in fluconazole SDD isolates, but not to frank resistance to fluconazole. The percentage of fluconazole non-susceptible isolates, as expected, was the highest in hospital B (9.1%), where fluconazole usage was greatest, and it varied considerably among the nine hospitals, ranging from 1.4 to 9.1%. These fluconazole SDD isolates also showed higher MIC 50 and MIC 90 values (0.125 and 1 mg/ml, respectively) against voriconazole than did all Candida isolates (0.03 and 0.125 mg/ml, respectively), suggesting a trend toward class resistance (data not shown). Most of the fluconazole non-susceptible Candida isolates were C. glabrata or C. krusei. However, the rate of fluconazole non-susceptible isolates may not directly reflect a higher frequency of C. glabrata and C. krusei at the hospitals because most of the C. glabrata isolates (72.9%) were fluconazole-susceptible and the isolation rate of C. krusei was low (0.8%). In addition, there was no statistically significant relationship between the percentage of C. glabrata and C. krusei isolates and antifungal usage at the hospitals.
Our study has some limitations. First, we only report total antifungal use data which were not broken down on the basis of treatment indication (prophylaxis or therapy) or other patient information (ICU location or malignancy, etc.). Second, there was a 6-month gap between the collection of data on antifungal usage and the recovery of the fungi from clinical specimens. However, antifungal usage at each hospital remained relatively stable during the 6 months before the collection of specimens and over the period of study. Thus, we do not think that this influenced our findings.
Conclusion
In conclusion, we performed a prospective multicenter study of antifungal use and antifungal susceptibility in Korea. We noted considerable variation in total antifungal usage among the nine Korean hospitals examined. The percentage of fluconazole-resistant isolates was low in all of the hospitals (0Á3.3%), and there was no correlation between antifungal usage and fluconazole resistance. However, the percentage of fluconazole non-susceptible isolates varied considerably among the nine hospitals, ranging from 1.4 to 9.1%, and there was a positive correlation between the percentage of fluconazole-non-susceptible Candida isolates and antifungal (total or fluconazole) usage. These findings offer the first evidence that increased use of fluconazole is significantly correlated with an increased number of fluconazole non-susceptible Candida isolates from clinical specimens. These findings support the importance of fluconazole usage in hospitals in relation to the fluconazole-susceptibility of Candida isolates.
